Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines


Bio-synonyms: describing biosimilars without saying ‘copycats’ or ‘knock-offs’

Terms such as ‘copycats’ and ‘knock-offs’ are inaccurate and misleading, say drugmakers. We ask therefore how industry and the media should refer to biosimilar products?

Cool with 'cats?

Bespak launches autoinjector for high viscosity formulations; signs global pharma deal

Bespak has launched an auto-injector designed to deliver higher viscosity drug formulations.

Samsung Bioepis contracts Catalent to help commercialize Benepali

Samsung Bioepis has contracted Catalent to provide fill finish services for its Enbrel (etanercept) biosimilar, Benepali.

China's Tot Biopharm starts work on second plant with eye on ADC market

Tot Biopharm has started work on a second monoclonal antibody (mAb) drug production plant at China’s Suzhou Industrial Park.

Merck completes expansion of Madrid Gonal-f API plant

Merck has completed the expansion of its biologics API manufacturing facility in Madrid, Spain increasing production capacity by 50%.

Pfizer: US Remicade biosimilar will launch at 15% discount in November

Pfizer’s Inflectra will become the first monoclonal antibody biosimilar available in the US when it is launched next month.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...